Rapid risk/outbreaks assessment aim at supporting the countries and the European Commission in their preparedness and response to a public health threat. They provide a timely summary and risk assessment of a public health threat for EU/EEA countries related to a specific event. They also include potential options for response. As outbreaks or public health events develop, ECDC may issue updated risk assessments.
This rapid risk assessment addresses the public health risk associated with the early occurrence of a large number of West Nile virus infections in the EU/EEA and EU neighbouring countries in 2018.
In September 2017, the Ministry of Health in Brazil declared the end of the 2016–2017 yellow fever outbreak in the country. The upsurge of human cases since December 2017 and the continuous non-human primate epizootics since September 2017 indicate a continued or resumed increase in yellow fever virus circulation in Brazil. Since January 2018, most of the yellow fever cases have been reported from São Paulo, Rio de Janeiro and Minas Gerais states.
This publication assesses the risk to EU/EEA countries and citizens associated with the ongoing outbreak of yellow fever in Brazil. This is the second update of a rapid risk assessment originally produced on 25 January 2017 and updated on 13 April 2017.
Italy is currently experiencing four clusters of autochthonous chikungunya cases in the cities of Anzio, Latina and Rome in the Lazio region, and the city of Guardavalle Marina in the Calabria region.
Two related clusters involving autochthonous transmission of chikungunya virus have been detected in the cities of Anzio and Rome. This rapid risk assessment provides detailed event background information and assesses the threat for the European Union.
This rapid risk assessment has been produced In the context of a cluster of four confirmed cases and one probable locally-acquired case of chikungunya in Var department, in southern France.
On 24 March 2017, the German authorities reported the contamination of a ‘do-it-yourself’ bacterial gene engineering CRISPR kit produced in the US. This publication assesses the risk related to the use of ‘do-it-yourself’ CRISPR-associated gene engineering kit contaminated with pathogenic bacteria.
This risk assessment contains updated advice to travellers and health professionals and the latest information on the epidemiological situation of yellow fever in Brazil.